To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital

被引:4
|
作者
Sruthi, Vadlakonda [1 ]
Reddy, Resu Neha [1 ]
Sowmini, K. [1 ]
Grace, Nagur Sharone [1 ]
机构
[1] Osmania Med Coll & Hosp, Dept Pharmacol, Turrebaz Rd, Hyderabad 500095, Telangana, India
关键词
Absolute eosinophil count; allergy; bepotastine; olopatadine; vernal keratoconjunctivitis;
D O I
10.4103/ijp.IJP_174_20
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
INTRODUCTION: Vernal conjunctivitis comprises 0.5% of allergic eye diseases. The study is intended to collate the effectiveness of drugs by observing the reduction in signs and symptoms. OBJECTIVES: The objective of the study is to evaluate the effectiveness and safety of olopatadine 0.1% ophthalmic drops with bepotastine besilate 1.5% ophthalmic drops in patients with vernal keratoconjunctivitis (VKC). MATERIALS AND METHODS: A randomized, open-label, comparative study conducted in Sarojini Devi Eye Hospital, Telangana. The study included 50 patients diagnosed with VKC, of which Group A and Group B were given olopatadine 0.1% ophthalmic drops and bepotastine besilate 1.5% ophthalmic drops, respectively, twice a day for 8 weeks. The reduction in signs and symptoms in both groups was compared. The observations and results were tabulated accordingly, and data were analyzed using the SPSS. The unpaired t-test is used as the test of significance in between two groups. P value is statistically significant when it is less than 0.05. RESULTS: Overall, 50 cases were included in the study, 72% of total patients were in the age group of 5-10 years, and 28% were in the age group of 11-15 years. There were 39 males and 11 females. After 8 weeks of follow-up, the mean reduction in the scoring of symptoms and signs provided better and quicker relief of watering, ocular discomfort, and conjunctival hyperemia with bepotastine 1.5% eye drops. Olopatadine 0.1% eye drops provided faster improvement in papillary hypertrophy. Both drugs were equally effective in reducing itching. Laboratory findings of absolute eosinophil count had no statistical significance in between the two groups. CONCLUSIONS: In this study, based on the evaluation of therapeutic performance, bepotastine eye drops proved quicker relief of symptoms and signs compared to olopatadine eye drops but was not statistically significant which would prove beneficial for the patients.
引用
收藏
页码:476 / 481
页数:6
相关论文
共 50 条
  • [31] Pharmacology, clinical efficacy and safety of bromfenac ophthalmic solution
    Fujishima, Hiroshi
    EXPERT REVIEW OF OPHTHALMOLOGY, 2007, 2 (04) : 543 - 549
  • [32] Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic Solution
    Garg, Prashant
    Mathur, Umang
    Sony, Parul
    Tandon, Radhika
    Morris, Timothy W.
    Comstock, Timothy L.
    ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2015, 4 (03): : 140 - 145
  • [33] THE EFFECT OF BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5% ON PRICK SKIN TEST REACTIVITY MEASURED WITH HISTAMINE CONTROLS
    Lanier, B.
    Jones, D.
    Marks, B.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A113 - A114
  • [34] Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model
    Lanier, BQ
    Finegold, I
    D'Arienzo, P
    Granet, D
    Epstein, AB
    Ledgerwood, GL
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (08) : 1227 - 1233
  • [35] SAFETY EVALUATION OF OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION 0.77% IN PEDIATRIC SUBJECTS WITH ASYMPTOMATIC EYES
    Meier, Edward John
    Narvekar, Abhijit
    Bae, Kyong
    Sall, Kenneth N.
    Wirta, David
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [36] Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis
    Fadlallah, Ali
    El Rami, Hala
    Fahd, Daoud
    Dunia, Ibrahim
    Bejjani, Riad
    Chlela, Elie
    Waked, Naji
    Jabbour, Elyse
    Fahed, Sharbel
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2012, 75 (03) : 178 - 182
  • [37] Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: A randomized, placebo-controlled, natural exposure, clinical trial
    Carr, Warner W.
    Nayak, Anjuli S.
    Ratner, Paul H.
    Gow, James A.
    McNamara, Timothy R.
    Williams, Jon I.
    ALLERGY AND ASTHMA PROCEEDINGS, 2013, 34 (03) : 247 - 254
  • [38] METHOD TO EVALUATE THE SAFETY OF AN OTC OPHTHALMIC SOLUTION IN NORMAL HUMAN VOLUNTEERS
    CALLAHAN, DR
    PARISH, LC
    NEVYAS, HJ
    JOURNAL OF THE SOCIETY OF COSMETIC CHEMISTS, 1979, 30 (02): : 67 - 71
  • [39] Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis
    Meier, Edward J.
    Torkildsen, Gail L.
    Gow, James A.
    McNamara, Timothy R.
    Gomes, Paul J.
    Williams, Jon I.
    ALLERGY AND ASTHMA PROCEEDINGS, 2012, 33 (03) : 265 - 274
  • [40] BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5% REDUCES NASAL CONGESTION WITH RAPID ONSET IN A CLINICAL MODEL OF ALLERGIC CONJUNCTIVITIS
    Torkildsen, G. L.
    Williams, J. I.
    Gow, J. A.
    Gomes, P. J.
    McNamara, T. R.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2009, 103 (05) : A130 - A130